By all indications, it looks as if Idenix Pharmaceuticals Inc. has caught the eye of its new neighbor, Novartis Pharma AG, which is taking a controlling interest in Idenix and its viral drug programs through a deal that could be worth up to at least $862 million. (BioWorld Today) Read More